| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 3,924,908 | |||
| Inventory | 22,286,693 | |||
| Prepaid expenses | 1,331,280 | |||
| Total current assets | 27,542,881 | |||
| In-process research and development | 73,400,000 | |||
| Total other assets | 73,400,000 | |||
| Total assets | 100,942,881 | |||
| Accounts payable | 13,234,684 | |||
| License payable | 22,650,000 | |||
| Accrued expenses | 4,093,124 | |||
| Due to related party-Related Party | 9,513,771 | |||
| Total current liabilities | 49,491,579 | |||
| Deferred tax liability | 2,784,960 | |||
| Note payable to related party-Related Party | 3,800,111 | |||
| Total liabilities | 56,076,650 | |||
| Common stock - 0.0001 par value 400,000,000 and 100,000,000 shares authorized at september 30, 2025 and 2024, respectively 83,513,442 and 71,552,402 shares issued and outstanding at september 30, 2025 and 2024, respectively | 8,351 | |||
| Additional paid-in capital | 108,897,836 | |||
| Accumulated deficit | -64,039,956 | |||
| Total stockholders equity | 44,866,231 | |||
| Total liabilities and stockholders equity | 100,942,881 | |||
CITIUS ONCOLOGY, INC. (CTOR)
CITIUS ONCOLOGY, INC. (CTOR)